Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Batiraxcept in Healthy Subjects
NCT03401528Phase 1Completed
- Sponsor
- Aravive, Inc.
- Start
- Jan 2018
- Primary completion
- Jun 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of batiraxcept in ovarian cancer and renal cell carcinoma (RCC) (4 arms), sponsored by Aravive, Inc. Primary endpoints: Safety and tolerability of AVB-S6-500 - Adverse events up to 6 weeks, Safety and tolerability of AVB-S6-500 - ECG up to 6 weeks and 3 more. Started Jan 2018; status: completed.
02
Drugs
batiraxcept
03
Conditions
ovarian cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03401528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401528.